Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line | Zendy

Xiaofeng Xu | Zendy; Yuhua Yan | Zendy; Qingying Xun | Zendy; Jiayu Shi | Zendy; Xiangyi Kong | Zendy; Jun Wu | Zendy; Huaijun Zhou | Zendy

Open Access

<p>Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line</p>

Author(s) -

Xiaofeng Xu,

Yuhua Yan,

Qingying Xun,

Jiayu Shi,

Xiangyi Kong,

Jun Wu,

Huaijun Zhou

Publication year - 2019

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s194064

Subject(s) - angiogenesis , gene silencing , endometrial cancer , cancer research , metastasis , small interfering rna , in vivo , medicine , vascular endothelial growth factor , apoptosis , cell growth , in vitro , cancer , cell culture , pharmacology , biology , vegf receptors , transfection , gene , biochemistry , genetics , microbiology and biotechnology

Angiogenesis is critical for the growth and metastasis of solid tumors and is, therefore, an important therapeutic target. Despite the great research advances in tumor therapies targeting vascular endothelial growth factor (VEGF), drug resistance frequently occurs, and further strategies targeting the tumor vasculature are of primary concern.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research